Information Provided By: 
Fly News Breaks for May 23, 2016
AGN
May 23, 2016 | 08:59 EDT
Cowen believes there is a fundamental misunderstanding as to Allergan's core commercial portfolio and its underlying growth and duration. The firm feels the company has one of the more durable and better growing core portfolios in the pharmaceuticals space. Cowen reiterated its Outperform rating and $400 price target on Allergan, saying It has one of the better new product cycles, an overlooked pipeline, and a healthy balance sheet.
News For AGN From the Last 2 Days
There are no results for your query AGN
